Disease-associated astrocytes (also known as reactive astrocytes) are astrocytes that adopt distinct molecular phenotypes in response to neuroinflammation, neurodegeneration, or injury. The A1/A2 classification, originally proposed by Liddelow et al. (2017), describes two polarized states: neurotoxic A1 astrocytes and neuroprotective A2 astrocytes[1].
Astrocytes are the most abundant glial cell type in the human brain, comprising approximately 20-40% of glial cells. Under normal conditions, they perform critical homeostatic functions including:
In response to CNS injury, disease, or infection, astrocytes undergo reactive astrogliosis, a process where they adopt disease-specific molecular signatures. The A1/A2 paradigm provides a framework for understanding the dual nature of this response.
A1 astrocytes upregulate genes associated with the complement cascade and synaptic elimination. Transcriptomic analysis has identified a characteristic gene expression profile:
| Gene | Function | Disease Relevance |
|---|---|---|
| C3 | Complement component 3 - mediates synaptic pruning | Elevated in AD, PD, ALS |
| C4 | Complement component 4 | Synapse loss |
| SERPINA3N | Serpinase A3N - protease inhibitor | Neuroinflammation |
| Amigo2 | Adhesion molecule with Ig domain 2 | Neurotoxicity |
| Ggb | Guanylate binding protein | Interferon response |
A1 astrocytes are characterized by several detrimental functions:
A2 astrocytes upregulate genes involved in tissue repair and neuroprotection:
| Gene | Function | Therapeutic Target |
|---|---|---|
| S100A10 | Calcium-binding protein | Anti-inflammatory |
| PTX3 | Pentraxin 3 - anti-inflammatory | Biomarker |
| CD109 | Cell surface glycoprotein | Tissue repair |
| Emp1 | Epithelial membrane protein 1 | Proliferation |
| Clcf1 | Cardiotrophin-like cytokine factor 1 | Neurotrophic |
A2 astrocytes exhibit beneficial functions:
The A1 phenotype is primarily induced by activated microglia through the following pathways:
A2 phenotype is promoted by:
| Strategy | Mechanism | Development Stage |
|---|---|---|
| Anti-C3 therapy | Block complement-mediated synaptic loss | Preclinical |
| TGF-β activation | Promote A2 phenotype | Research |
| IL-10 enhancement | Anti-inflammatory pathways | Preclinical |
| Microglial inhibition | Prevent A1 induction | Early clinical |
| PPARγ agonists | Modulate astrocyte phenotype | Clinical trials |
Several approaches targeting astrocyte reactivity are in development:
The study of Disease Associated Astrocytes (A1 A2) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Liddelow et al. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. Nature, 541(7638), 481-487 ↩︎
Zhou et al. (2020). A1 astrocytes contribute to synaptic elimination in Alzheimer's disease. Nature Neuroscience, 23(3), 327-338 ↩︎
Clarke et al. (2018). IL-1α is essential for oligodendrocyte viability and glial scarring after spinal cord injury. Nature Communications, 9(1), 2143 ↩︎